Janssen Research & Development

34 articles with Janssen Research & Development

• Resolution Advancing Development of Cell-Free DNA Companion Diagnostic for Prostate Cancer through Collaboration with Janssen

  6/19/2019

  Liquid biopsy assay with recent Breakthrough Device Designation from FDA is being used to screen patients with prostate cancer for HRD mutations and deletions as part of phase II and III clinical studies

• SomaLogic announces new collaboration with Janssen Research & Development

  4/11/2019

  Companies to share proteomic and clinical data to drive new drug discovery and development, and precision health management

• MorphoSys Announces that its Licensee Janssen has Expanded Clinical Development of Guselkumab (Tremfya(R)) into Ulcerative Colitis

  1/17/2019

  MorphoSys AG announced that its licensee Janssen Research & Development, LLC (Janssen), has further expanded the clinical development of guselkumab (Tremfya(R)) into ulcerative colitis (UC).

• MorphoSys Announces Its Licensee Janssen Initiated a Phase 2 Study (NOVA) to Evaluate Guselkumab in Hidradenitis Suppurativa

  11/21/2018

  MorphoSys AG announced today that its licensee Janssen Research & Development, LLC (Janssen) initiated a phase 2 clinical study of guselkumab in patients with moderate to severe hidradenitis suppurativa (HS), a chronic skin disease also known as acne inversa.

• Johnson & Johnson Innovation Launches Reimagining Respiratory Protection QuickFire Challenge in Collaboration with the U.S. Department of Health and Human Services

  10/30/2018

  Johnson & Johnson Innovation, JLABS teams with the Biomedical Advanced Research and Development Authority (BARDA) to advance new technologies to improve global pandemic preparedness against respiratory infection outbreaks

• Immugenyx Enters Collaboration with Johnson & Johnson Innovation

  10/16/2018

  Hemogenyx Pharmaceuticals Plc announces that its wholly owned subsidiary, Immugenyx, LLC (“Immugenyx”), has entered into a collaboration agreement with Janssen Research & Development, LLC (“Janssen”), one of the Janssen Pharmaceutical Companies of Johnson & Johnson. The agreement was facilitated by Johnson & Johnson Innovation LLC.

• Sierra Oncology and Janssen Sign Supply Agreement for Prostate Cancer Study

  2/27/2018

  Janssen to supply PARP inhibitor niraparib for Sierra's Phase 1b/2 combination trial with Chk1 inhibitor SRA737

• Janssen R&D's New Data for DARZALEX (daratumumab) Presented at ASH 2017 Showed Feasibility of Subcutaneous Use and Promise of DARZALEX as a Treatment for Smoldering Multiple Myeloma

  12/12/2017

  Janssen R&D today announced new data from the Phase 1b PAVO clinical study, which demonstrated that the subcutaneous delivery of DARZALEX had a manageable safety profile and a 12 percent rate of infusion reactions in patients with relapsed or refractory multiple myeloma.

• Janseen Biotech Release: DARZALEX (daratumumab) Combination Regimen Significantly Improved Outcomes for Newly Diagnosed Multiple Myeloma Patients Who are Transplant Ineligible

  12/12/2017

  Janssen R&D today announced data from the Phase 3 ALCYONE study, showing that DARZALEX in combination with bortezomib, melphalan and prednisone significantly improved clinical outcomes, including reducing the risk of disease progression or death by 50 percent, in patients with newly diagnosed multiple myeloma who are ineligible for ASCT.

• Sustained Benefit in Patients With Relapsed/Refractory Mantle Cell Lymphoma Demonstrated by 3 1/2 -Year Follow-Up Data of IMBRUVICA (ibrutinib)

  12/11/2017

  The extended follow-up data demonstrated that patients treated with IMBRUVICA earlier (after first relapse) experienced the best clinical outcomes, in terms of both efficacy and tolerability.

• Janssen Submits Supplemental NDA to FDA Seeking New Indications for XARELTO (rivaroxaban) for Patients With Chronic Coronary and/or Peripheral Artery Disease (CAD/PAD)

  12/11/2017

  This application is based on data from the landmark COMPASS study, the only randomized trial to investigate a Factor Xa inhibitor for preventing major CV events in this population.

• Janssen's New Real-World Analysis Shows INVOKANA (canagliflozin) and Other SGLT2 Inhibitors Reduced the Risk of Death and Cardiovascular Events Compared to Other Diabetes Medicines

  11/20/2017

  A new real-world analysis of adults with type 2 diabetes and established CVD shows adult patients who initiated therapy with INVOKANA or another SGLT2i had a 43 percent reduced risk for ACM and hospitalization for HHF after an average of 1.6 years, compared to similar patients who initiated treatment with a non-SGLT2i medication using an ITT approach.

• Janssen R&D's INVOKANA (canagliflozin) Demonstrates Cardiovascular (CV) Risk Reductions in Type 2 Diabetes Patients With and Without a History of Prior CV Events

  11/14/2017

  INVOKANA also achieved similar and proportional risk reductions for hospitalization due to heart failure and renal outcomes in each of the primary and secondary prevention groups.

• Janssen's New Phase II Data Show Treatment With TREMFYA (guselkumab) Improved Psoriatic Arthritis Symptoms Through One Year

  11/7/2017

  According to findings presented at the 2017 ACR/ARHP Annual Meeting, more than 70 percent of patients receiving TREMFYA 100 mg subcutaneous injections achieved at least a 20 percent improvement in signs and symptoms of disease using observed data at week 56.

• Janssen R&D's STELARA (ustekinumab) Shows Positive Results In Treatment of Systemic Lupus Erythematosus in Phase II Trial

  11/6/2017

  The study met the primary endpoint, with a significantly higher proportion of patients in the STELARA group showing improvements in lupus disease activity as measured by the SLE Responder Index (SRI)-4 response at week 24, compared with patients receiving placebo.

• 

  Janssen R&D's INVOKANA (canagliflozin) Significantly Improved Renal Outcomes and Demonstrated Pot...

  11/3/2017

  The renal analyses showed that compared to placebo, canagliflozin successfully reduced the risk of kidney disease progression.

• ASH 2017: Janssen to Present 40 Abstracts, Including 8 Oral Presentations, With New Data on DARZALEX (Daratumumab), IMBRUVICA (Ibrutinib) and Other Compounds From Robust Portfolio

  11/1/2017

  New data for the immunotherapy DARZALEX (daratumumab) and first-in-class BTK inhibitor IMBRUVICA (ibrutinib) are among eight oral presentations from Janssen Research & Development, LLC, to be featured at the 59th American Society of Hematology Annual Meeting & Exhibition taking place December 9-12, in Atlanta, GA. 

• BioMed X Announces Biomedical Research Collaboration with Janssen

  10/26/2017

  BioMed X announced today a collaboration agreement with Janssen Research & Development to foster early-stage preclinical biomedical research and development projects.

• Janssen R&D Submits Supplemental New Drug Application (sNDA) To U.S. FDA Seeking New Indication For Invokana (CANAGLIFLOZIN) To Reduce The Risk Of Major Adverse Cardiovascular Events (MACE) Based On Landmark Canvas Program

  10/2/2017

• Janssen R&D Release: U.S. FDA Accepts For Review The Application Of Ibrutinib (IMBRUVICA) For Chronic Graft-Versus-Host-Disease (Cgvhd) After Failure Of One Or More Lines Of Systemic Therapy

  4/4/2017